Received: 9 January 2019
Accepted: 6 March 2019
First Online: 25 March 2019
Ethics approval and consent to participate
: The study was approved by the ethics committee of our university (approval number 20130506.)
: The study was followed by instruction of the ethics committee of our university.
: NK has no conflicts of interest to declare. KS has received research grants from Eisai, Bristol-Myers Squibb, Kissei Pharmaceutical, Daiichi-Sankyo, speaking fees from Abbie Japan, Astellas Pharma, Bristol-Myers Squibb., Chugai Pharmaceutical, Eisai, Fuji Film Limited, Janssen Pharmaceutical, Kissei Pharmaceutical, Mitsubishi Tanabe Pharmaceutical, Pfizer Japan, Shionogi, and Takeda Pharmaceutical, UCB Japan. Consulting fees from Abbie, Pfizer Japan. TT has received grants from Chugai Pharmaceutical Co. Ltd., Pfizer Japan Inc., and Takeda Pharmaceutical Co. Ltd. and income from AbbVie GK., Asahi Kasei Medical K.K., Astellas Pharma Inc., Astra Zeneca K.K., Bristol-Myers K.K., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Novartis Pharma K.K., Pfizer Japan Inc., and Takeda Pharmaceutical Co. Ltd.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.